Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Rein Therapeutics (RNTX) Assets Average (2017 - 2025)

Rein Therapeutics filings provide 9 years of Assets Average readings, the most recent being $38.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Assets Average fell 53.21% year-over-year to $38.9 million, compared with a TTM value of $38.9 million through Dec 2025, down 53.21%, and an annual FY2025 reading of $43.2 million, down 48.66% over the prior year.
  • Assets Average hit $38.9 million in Q4 2025 for Rein Therapeutics, down from $55.6 million in the prior quarter.
  • The five-year high for Assets Average was $106.8 million in Q3 2024, with the low at $13.4 million in Q3 2023.
  • Median Assets Average over the past 5 years was $53.6 million (2021), compared with a mean of $53.3 million.
  • The sharpest move saw Assets Average plummeted 57.92% in 2023, then soared 696.69% in 2024.
  • Year by year, Assets Average stood at $51.6 million in 2021, then tumbled by 52.31% to $24.6 million in 2022, then surged by 141.33% to $59.4 million in 2023, then soared by 40.04% to $83.2 million in 2024, then tumbled by 53.21% to $38.9 million in 2025.
  • According to Business Quant data, Assets Average over the past three periods came in at $38.9 million, $55.6 million, and $57.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.